Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study to Assess the Blood Levels and Safety of Olaparib in Patients With Advanced Solid Tumours and Normal or Impaired Kidney Function

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01894256
Recruitment Status : Completed
First Posted : July 10, 2013
Results First Posted : April 19, 2016
Last Update Posted : October 13, 2016
Sponsor:
Information provided by (Responsible Party):
AstraZeneca

Brief Summary:
This is a 2-part study in patients with advanced solid tumours. Part A will investigate the PK of olaparib in patients with mild or moderate renal impairment compared to patients with normal renal function; Part B will allow eligible study patients continued access to olaparib after the PK phase and will provide additional safety data.

Condition or disease Intervention/treatment Phase
Solid Tumours Drug: Olaparib tablet dosing Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 56 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Official Title: An Open-label, Non-randomised, Multicentre, Comparative, Phase I Study of the Pharmacokinetics, Safety and Tolerability of Olaparib Following a Single Oral 300 mg Dose to Patients With Advanced Solid Tumours and Normal Renal Function or Renal Impairment
Study Start Date : November 2013
Actual Primary Completion Date : March 2015
Actual Study Completion Date : February 2016

Resource links provided by the National Library of Medicine

Drug Information available for: Olaparib

Arm Intervention/treatment
Normal renal function
Patients with calculated serum creatinine clearance ≥81 mL/min (using Cockcroft-Gault equation).
Drug: Olaparib tablet dosing
Part A - single 300mg oral dose olaparib (administered as 2x150mg tablets) Part B - 300mg oral dose olaparib (administered as 2x150mg tablets) bd

Mild renal impairment
Patients with calculated serum creatinine clearance 51-80 mL/min (using Cockcroft-Gault equation).
Drug: Olaparib tablet dosing
Part A - single 300mg oral dose olaparib (administered as 2x150mg tablets) Part B - 300mg oral dose olaparib (administered as 2x150mg tablets) bd

Moderate renal impairment
Patients with calculated serum creatinine clearance 31-50 mL/min (using Cockcroft-Gault equation).
Drug: Olaparib tablet dosing
Part A - single 300mg oral dose olaparib (administered as 2x150mg tablets) Part B - 300mg oral dose olaparib (administered as 2x150mg tablets) bd




Primary Outcome Measures :
  1. Cmax of Olaparib [ Time Frame: Part A: pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72 and 96 hours post-dose ]
    Maximum plasma drug concentration of olaparib

  2. AUC of Olaparib [ Time Frame: Part A: pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72 and 96 hours post-dose ]
    Area under plasma concentration-time curve from zero to infinity of olaparib

  3. AUC0-t of Olaparib [ Time Frame: Part A: pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72 and 96 hours post-dose ]
    Area under plasma concentration-time curve from zero to the last measurable time point of olaparib

  4. Tmax of Olaparib [ Time Frame: Part A: pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72 and 96 hours post-dose ]
    Time to reach maximum plasma concentration of olaparib

  5. Vz/F of Olaparib [ Time Frame: Part A: pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72 and 96 hours post-dose ]
    Apparent volume of distribution of olaparib

  6. CL/F of Olaparib [ Time Frame: Part A: pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72 and 96 hours post-dose ]
    Apparent plasma clearance of olaparib

  7. CLR of Olaparib [ Time Frame: Part A: Day 1, 0-12 hours and 12-24 hours post-dose ]
    Renal clearance of olaparib, calculated as the ratio of amount of drug excreted over 24 hours to AUC0-24

  8. t1/2 of Olaparib [ Time Frame: Part A: pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72 and 96 hours post-dose ]
    Terminal half-life of olaparib


Other Outcome Measures:
  1. Protein Binding of Olaparib [ Time Frame: Part A: Day 1, 1 hour post-dose ]
    Degree to which olaparib binds to the proteins within blood plasma

  2. Free Cmax of Olaparib [ Time Frame: Part A: Day 1, 1 hour post-dose ]
    Cmax of unbound olaparib; calculated by multiplying total Cmax value by estimated protein binding

  3. Free AUC of Olaparib [ Time Frame: Part A: Day 1, 1 hour post-dose ]
    AUC of unbound olaparib; calculated by multiplying total AUC by estimated protein binding

  4. CL/F of Unbound Olaparib [ Time Frame: Part A: Day 1, 1 hour post-dose ]
    Calculated from dose divided by free AUC



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion criteria:-

For inclusion in the study as a patient with renal impairment, the following criterion must be met:

  1. Patients must have stable renal impairment (moderate or mild), depending on creatinine clearance estimated using the Cockcroft-Gault equation (moderate 31 to 50 mL/min; mild 51 to 80 mL/min), for at least 2 months prior to the start of the study. For inclusion in the study as a patient with normal renal function, the following criterion must be met:
  2. Calculated serum creatinine clearance greater than or equal to 81 mL/min (using Cockcroft-Gault equation). All patients must fulfil the following criteria:
  3. Provision of written informed consent prior to any study specific procedures .
  4. Patients must be greater than or equal to 18 and less than or equal to 75 years of age.
  5. Histologically or, where appropriate, cytologically confirmed malignant solid tumour refractory or resistant to standard therapy or for which no suitable effective standard therapy exists.
  6. BMI between 18-30 kg/m2.
  7. Normal liver and bone marrow function measured within 28 days prior to administration of IP as defined below: Haemoglobin (Hb) greater than or equal to 10.0 g/dL, with no blood transfusions in the previous 28 days.

    Absolute neutrophil count (ANC) greater than or equal to 1.5 x 109/L. White blood cells (WBC) greater than 3 x 109/L. Platelet count greater than or equal to 100 x 109/L. Total bilirubin less than or equal to 1.5 x institutional upper limit of normal (ULN) (except in the case of Gilbert's disease).

    Aspartate aminotransferase or serum glutamic oxaloacetic transaminase (AST), alanine aminotransferase or serum glutamic pyruvic transaminase (ALT) less than or equal to 2.5 x institutional ULN unless liver metastases are present in which case it must be less than or equal to 5x ULN.

  8. Eastern Cooperative Oncology Group (ECOG) performance status less than or equal to 2.
  9. Patients must have a life expectancy greater than or equal to 12 weeks.
  10. Evidence of non childbearing status for women of childbearing potential, or postmenopausal status: negative urine or serum pregnancy test within 28 days of study treatment, confirmed prior to treatment on Day 1 of the first treatment period in Part A. Postmenopausal is defined as:

    Amenorrheic for 1 year or more following cessation of exogenous hormonal treatments.

    Luteinising hormone and follicle-stimulating hormone levels in the postmenopausal range for women under 50 years of age.

    Radiation-induced oophorectomy with last menses greater than 1 year ago. Chemotherapy-induced menopause with greater than 1 year interval since last menses Surgical sterilisation (bilateral oophorectomy or hysterectomy).

  11. Patients are willing and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and examinations.
  12. Patients must be on a stable concomitant medication regimen (with the exception of electrolyte supplements), defined as no changes in medication or in dose within 2 weeks prior to start of olaparib dosing, except for bisphosphonates, denosumab and corticosteroids, which should be stable for at least 4 weeks prior to start of olaparib dosing.

Exclusion criteria:-

Patients must not enter the study if any of the following exclusion criteria are fulfilled:

  1. Involvement in the planning and/or conduct of the study (applies to both AstraZeneca staff, its agents and/or staff at the study site).
  2. Previous enrolment in the present study.
  3. Participation in another clinical study with an investigational medicinal product (IP) during the last 14 days (or a longer period depending on the defined characteristics of the agent used).
  4. Renal transplant and end stage renal disease (ESRD) patients.
  5. Patients receiving any systemic chemotherapy or radiotherapy (except for palliative reasons) within 2 weeks prior to study treatment (or a longer period depending on the defined characteristics of the agents used). The patient can receive a stable dose of bisphosphonates or denosumab for bone metastases before and during the study as long as these were started at least 4 weeks prior to treatment.
  6. Patients who have received or are receiving inhibitors or inducers of CYP3A4 within the washout period.
  7. For Part A only, drugs which affect creatinine clearance such as cephalosporin antibiotics, ascorbic acid, trimethoprim, cimetidine and quinine should not be used within the 7 days prior to dosing with olaparib.
  8. Treatment in the previous 3 months with any drug known to have a well-defined potential for hepatotoxicity (eg, halothane).
  9. Persistent toxicities (greater than or equal to CTCAE Grade 2) caused by previous cancer therapy, excluding alopecia.
  10. Patients with myelodysplastic syndrome/acute myeloid leukaemia.
  11. Patients with symptomatic uncontrolled brain metastases. A scan to confirm the absence of brain metastases is not required. Patients with asymptomatic brain metastases or with symptomatic but stable brain metastases can receive a stable dose of corticosteroids before and during the study as long as these were started at least 4 weeks prior to treatment.
  12. Major surgery within 2 weeks of starting study treatment and patients must have recovered from any effects of major surgery.
  13. Patients considered a poor medical risk due to a serious uncontrolled medical disorder, non malignant systemic disease, uncontrolled seizures, or active uncontrolled infection. Examples include, but are not limited to, uncontrolled ventricular arrhythmia, recent (within 3 months) myocardial infarction, uncontrolled major seizure disorder, unstable spinal cord compression, superior vena cava syndrome, extensive bilateral interstitial lung disease on high resolution computer tomography (HRCT) scan, or any psychiatric disorder that prohibits obtaining informed consent.
  14. Patients with a history of heart failure or left ventricular dysfunction.
  15. Patients who have gastric, gastro-oesophageal or oesophageal cancer.
  16. Patients unable to swallow orally administered medication and patients with gastrointestinal disorders or significant gastrointestinal resection likely to interfere with the absorption of olaparib.
  17. Breastfeeding women.
  18. Immunocompromised patients eg, patients who are known to be serologically positive for human immunodeficiency virus (HIV).
  19. Patients with known active hepatic disease (eg, hepatitis B or C).
  20. Patients with a known hypersensitivity to olaparib or any of the excipients of the product.
  21. Resting ECG at screening with measurable QTc greater than 470 msec at 2 or more time points within a 24 hour period or family history of long QT syndrome.
  22. Clinical judgment by the investigator that the patient should not participate in the study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01894256


Locations
Layout table for location information
Belgium
Research Site
Brussels (Jette), Belgium
Research Site
Edegem, Belgium
Research Site
Leuven, Belgium
Research Site
Liege, Belgium
Research Site
Wilrijk, Belgium
Denmark
Research Site
Herlev, Denmark
Research Site
København Ø, Denmark
France
Research Site
Bordeaux, France
Research Site
Dijon, France
Netherlands
Research Site
Amsterdam, Netherlands
Research Site
Maastricht, Netherlands
United Kingdom
Research Site
Newcastle Upon Tyne, United Kingdom
Research Site
Surrey, United Kingdom
Sponsors and Collaborators
AstraZeneca
Investigators
Layout table for investigator information
Study Director: Anitra Fielding AstraZeneca Senior Research Physician
Principal Investigator: Christian Rolfo UZ Antwerpen

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: AstraZeneca
ClinicalTrials.gov Identifier: NCT01894256     History of Changes
Other Study ID Numbers: D0816C00006
2013-002225-30 ( EudraCT Number )
First Posted: July 10, 2013    Key Record Dates
Results First Posted: April 19, 2016
Last Update Posted: October 13, 2016
Last Verified: August 2016

Keywords provided by AstraZeneca:
oncology,
cancer,
neoplasm,
anticancer drug,
pharmacokinetics,
area under curve,
olaparib,
solid tumour,
mild renal impairment,
moderate renal impairment

Additional relevant MeSH terms:
Layout table for MeSH terms
Olaparib
Poly(ADP-ribose) Polymerase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents